Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients

Immunology and Cell Biology

Volumn 90, Issue 1, 2012, Pages 109-115

  Sanchez Correa, Beatriz ^a   Gayoso, Inmaculada ^b   Bergua, Juan M ^c   Casado, Javier G ^a   Morgado, Sara ^a   Solana, Rafael ^b   Tarazona, Raquel ^a  

^a UNIVERSITY OF EXTREMADURA   (Spain)

^b UNIVERSITY OF CÓRDOBA   (Spain)

^c HOSPITAL SAN PEDRO DE ALCÁNTARA   (Spain)

Author keywords

acute myeloid leukemia; aging; cancer; DNAM 1; natural killer cells

Indexed keywords

DNAM 1 PROTEIN; NECTIN 2; RECEPTOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BLAST CELL; CANCER CELL CULTURE; CELL ACTIVATION; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; NATURAL KILLER CELL; PROTEIN EXPRESSION;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; CELL ADHESION MOLECULES; CELLS, CULTURED; COCULTURE TECHNIQUES; DOWN-REGULATION; FEMALE; FLOW CYTOMETRY; HUMANS; K562 CELLS; KILLER CELLS, NATURAL; LEUKEMIA, MYELOID; LIGANDS; MALE; MIDDLE AGED; NEOPLASTIC STEM CELLS; RECEPTORS, VIRUS; YOUNG ADULT;

EID: 84855445932     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2011.15     Document Type: Article

References (35)

1. Caligiuri MA. Human natural killer cells. Blood 2008; 112: 461-469.
2. Bryceson YT, March ME, Ljunggren HG, Long EO. Activation, coactivation, and costimulation of resting human natural killer cells. Immunol Rev 2006; 214: 73-91. (Pubitemid 44707903)
3. Burgess SJ, Maasho K, Masilamani M, Narayanan S, Borrego F, Coligan JE. The NKG2D receptor: immunobiology and clinical implications. Immunol Res 2008; 40: 18-34. (Pubitemid 351378033)
4. Solana R, Casado JG, Delgado E, Dela Rosa O, Marin J, Duran E et al. Lymphocyte activation in response to melanoma: interaction of NK-associated receptors and their ligands. Cancer Immunol Immunother 2007; 56: 101-109. (Pubitemid 44812452)
5. Verheyden S, Demanet C. NK cell receptors and their ligands in leukemia. Leukemia 2008; 22: 249-257. (Pubitemid 351250528)
6. Becknell B, Caligiuri MA. Natural killer cells in innate immunity and cancer. JImmunother 2008; 31: 685-692.
7. Shibuya A, Campbell D, Hannum C, Yssel H, Franz-Bacon K, Mc Clanahan T et al. DNAM-1, a novel adhesion molecule involved inthecytolytic function of T lymphocytes. Immunity1996; 4: 573-581. (Pubitemid 26233311)
8. Kojima H, Kanada H, Shimizu S, Kasama E, Shibuya K, Nakauchi H et al. CD226 mediates platelet and megakaryocytic cell adhesion tovascular endothelial cells. J Biol Chem 2003; 278: 36748-36753. (Pubitemid 37140008)
9. Castriconi R, Dondero A, Corrias MV, Lanino E, Pende D, Moretta L et al. Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction. Cancer Res 2004; 64: 9180-9184. (Pubitemid 39665534)
10. Bottino C, Castriconi R, Pende D, Rivera P, Nanni M, Carnemolla B et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med 2003; 198: 557-567. (Pubitemid 37040390)
11. Tahara-Hanaoka S, Shibuya K, Onoda Y, Zhang H, Yamazaki S, Miyamoto A et al. Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112). Int Immunol 2004; 16: 533-538. (Pubitemid 38489427)
12. Pende D, Castriconi R, Romagnani P, Spaggiari GM, Marcenaro S, Dondero A et al. Expressionof the DNAM-1 ligands, Nectin-2 (CD112)and poliovirus receptor (CD155), on dendritic cells: relevance for natural killer-dendritic cell interaction. Blood 2006; 107:2030-2036. (Pubitemid 43289387)
13. Pende D, Spaggiari GM, Marcenaro S, Martini S, Rivera P, Capobianco A et al. Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112). Blood 2005; 105: 2066-2073. (Pubitemid 40731793)
14. El-Sherbiny YM, Meade JL, Holmes TD, Mc Gonagle D, Mackie SL, Morgan AW et al. The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. Cancer Res 2007; 67: 8444-8449. (Pubitemid 47437416)
15. Carlsten M, Bjorkstrom NK, Norell H, Bryceson Y, van HT, Baumann BC et al. DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells. Cancer Res 2007; 67: 1317-1325.
16. Casado JG, Pawelec G, Morgado S, Sanchez-Correa B, Delgado E, Gayoso I et al. Expression of adhesion molecules and ligands for activating and costimulatory recep-tors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines. Cancer Immunol Immunother 2009; 58: 1517-1526.
17. Lowdell MW, Craston R, Samuel D, Wood ME, O'Neill E, Saha V et al. Evidence that continued remission in patients treated for acute leukaemia is dependent upon autologous natural killer cells. Br JHaematol 2002; 117: 821-827. (Pubitemid 34639242)
18. Costello RT, Fauriat C, Sivori S, Marcenaro E, Olive D. NK cells: innate immunity against hematological malignancies? Trends Immunol 2004; 25: 328-333. (Pubitemid 38610357)
19. Ingram W, Chan L, Guven H, Darling D, Kordasti S, Hardwick N et al. Human CD80/IL2 lentivirus-transduced acute myeloid leukaemia (AML) cells promote natural killer (NK) cell activation and cytolytic activity: implications for a phase I clinical study. Br JHaematol 2009; 145: 749-760.
20. Stone RM, O'Donnell MR, Sekeres MA. Acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2004; 1: 98-117.
21. Sekeres MA. Treatmentofolderadultswith acute myeloid leukemia: stateoftheartand currentperspectives. Haematologica 2008; 93: 1769-1772.
22. Sekeres MA, Kalaycio ME. Definition of remission, prognosis, and follow-up. In: Sekeres MA, Kalaycio ME, Bolwell BJ (eds.). Clinical Malignant Hematology. Mc Graw-Hill Medical: New York, 2007, 83-90.
23. Costello RT, Sivori S, Marcenaro E, Lafage-Pochitaloff M, Mozziconacci MJ, Reviron D et al. Defective expression and function of natural killer cell-triggering receptors in patientswith acutemyeloid leukemia. Blood 2002; 99: 3661-3667. (Pubitemid 34534536)
24. Fauriat C, Just-Landi S, Mallet F, Arnoulet C, Sainty D, Olive D et al. Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCR dull phenotype induction. Blood 2007; 109:323-330. (Pubitemid 46053073)
25. Szczepanski MJ, Szajnik M, Welsh A, Foon KA, Whiteside TL, Boyiadzis M. Interleukin-15 enhances natural killer cell cytotoxicity in patientswith acute myeloid leukemia by upregulating the activating NK cell receptors. Cancer Immunol Immunother 2010; 59: 73-79.
26. Ogata K, An E, Shioi Y, Nakamura K, Luo S, Yokose N et al. Association between natural killer cell activity and infection in immunologically normal elderly people. Clin Exp Immunol 2001; 124: 392-397. (Pubitemid 32701699)
27. Solana R, Pawelec G, Tarazona R. Aging and innate immunity. Immunity 2006; 24: 491-494. (Pubitemid 43728154)
28. Plackett TP, Boehmer ED, Faunce DE, Kovacs EJ. Aging and innate immune cells. JLeukoc Biol 2004; 76: 291-299. (Pubitemid 39006941)
29. Carlsten M, Norell H, Bryceson YT, Poschke I,Schedvins K, Ljunggren HGet al. Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells. J Immunol 2009; 183: 4921-4930.
30. Chan CJ, Andrews DM, Mc Laughlin NM, Yagita H, Gilfillan S, Colonna M et al. DNAM-1/CD155 interactions promote cytokine and NK cell-mediated suppression of poorly immunogenic melanoma metastases. JImmunol 2010; 184: 902-911.
31. Gilfillan S, Chan CJ, Cella M, Haynes NM, Rapaport AS, Boles KS et al. DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J Exp Med 2008; 205: 2965-2973.
32. Carlsten M, Baumann BC, Simonsson M, Jadersten M, Forsblom AM, Hammarstedt C et al. Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34+ blasts in myelodysplastic syndrome. Leukemia 2010; 24: 1607-1616.
33. Coudert JD, Zimmer J, Tomasello E, Cebecauer M, Colonna M, Vivier E et al. Altered NKG2Dfunction in NKcells induced by chronic exposureto NKG2D ligand-expressing tumorcells. Blood 2005; 106: 1711-1717. (Pubitemid 41208585)
34. Roda-Navarro P, Vales-Gomez M, Chisholm SE, Reyburn HT. Transfer of NKG2D and MICB at the cytotoxic NK cell immune synapse correlates with a reduction in NK cell cytotoxic function. Proc Natl Acad Sci USA 2006; 103: 11258-11263. (Pubitemid 44156506)
35. Waldhauer I, Steinle A. NK cellsand cancer immunosurveillance. Oncogene 2008; 27: 5932-5943.